小儿干细胞移植患者在接受伏立康唑、两性霉素B脂质体或米卡芬净进行抗真菌预防时发生的侵袭性真菌感染
Invasive Fungal Infections While on Voriconazole, Liposomal Amphotericin B, or Micafungin for Antifungal Prophylaxis in Pediatric Stem Cell Transplant Patients.
作者信息
Bui Annie, Nguyen Veronica, Hsu Christina, Hyde Ben, Simms-Waldrip Tiffany
出版信息
J Pediatr Pharmacol Ther. 2019 May-Jun;24(3):220-226. doi: 10.5863/1551-6776-24.3.220.
OBJECTIVE
This study aimed to report the incidence of invasive fungal infections (IFIs) in pediatric hematopoietic stem cell transplant (HSCT) patients who received voriconazole, liposomal amphotericin B (L-AMB), or micafungin for primary antifungal prophylaxis (PAP).
METHODS
Using data retrospectively collected from institution's electronic records, this study analyzed the incidence of IFIs in pediatric HSCT patients between November 2012 and November 2016.
RESULTS
A total of 103 patients were screened. Of the 84 patients who met inclusion criteria, 76.2%, 29.8%, and 19% patients received voriconazole, L-AMB, and micafungin, respectively. The incidence of overall IFIs was 2.08 per 1000 prophylaxis days. There were 2 mold infections identified in 2 patients. Among 3 antifungal agents, the rates of IFIs were 2.67 per 1000 prophylaxis days in L-AMB group, 2.08 per 1000 prophylaxis days in micafungin group, and 1.17 per 1000 prophylaxis days in voriconazole group.
CONCLUSION
Patients who received L-AMB or micafungin had higher rates of IFIs than those who received voriconazole for PAP.
目的
本研究旨在报告接受伏立康唑、两性霉素B脂质体（L-AMB）或米卡芬净进行一级抗真菌预防（PAP）的儿科造血干细胞移植（HSCT）患者侵袭性真菌感染（IFI）的发生率。
方法
利用从机构电子记录中回顾性收集的数据，本研究分析了2012年11月至2016年11月期间儿科HSCT患者IFI的发生率。
结果
共筛选出103例患者。在符合纳入标准的84例患者中，分别有76.2%、29.8%和19%的患者接受了伏立康唑、L-AMB和米卡芬净治疗。IFI的总发生率为每1000个预防日2.08例。在2例患者中发现了2例霉菌感染。在3种抗真菌药物中，L-AMB组IFI发生率为每1000个预防日2.67例，米卡芬净组为每1000个预防日2.08例，伏立康唑组为每1000个预防日1.17例。
结论
接受L-AMB或米卡芬净进行PAP的患者IFI发生率高于接受伏立康唑的患者。
Zotero 插件